(112) indicates that serum NETs levels are an effective predictor of PD-1 inhibitor response used in the treatment of advanced non-small cell lung cancer (NSCLC) and reflect the neutrophil-to-lymphocyte ratio (NLR) in the tissue and the likelihood of immune-related adverse events (IrAEs). Here, PDCD1 is linked to non-small cell lung carcinoma.